- Home
- CGEM vs ADV Comparison
CGEM vs ADV Comparison
Compare CGEM & ADV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGEM | ADV |
|---|---|---|
| Founded | 2016 | 1987 |
| Country | United States | United States |
| Employees | N/A | 69000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 794.7M | 209.6M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | CGEM | ADV |
|---|---|---|
| Price | $12.77 | $0.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | ★ $30.11 | $1.83 |
| AVG Volume (30 Days) | 756.0K | ★ 847.1K |
| Earning Date | 03-10-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $0.63 |
| Revenue Next Year | $79.85 | $0.45 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.68 | $0.49 |
| 52 Week High | $16.74 | $2.11 |
Technical Indicators
Market Signals| Indicator | CGEM | ADV |
|---|---|---|
| Relative Strength Index (RSI) | 40.88 | 55.53 |
| Support Level | $11.43 | $0.51 |
| Resistance Level | $13.21 | $0.97 |
| Average True Range (ATR) | 0.82 | 0.08 |
| MACD | -0.38 | 0.02 |
| Stochastic Oscillator | 2.28 | 75.08 |
Price Performance
Historical ComparisonAbout CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
About ADV Advantage Solutions Inc.
Advantage Solutions Inc is a omnichannel retail solutions agency in North America, uniquely positioned at the intersection of consumer-packaged goods (CPG) brands and retailers.